Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ENTX Entera Bio Ltd
- Stocks
- Healthcare
- NASDAQ: ENTX
Price (delayed)
$2.05
Market cap
$93.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$72.82M
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due
Highlights
The equity has surged by 140% since the previous quarter and by 119% year-on-year
ENTX's quick ratio has surged by 71% since the previous quarter and by 55% year-on-year
The EPS is up by 7% year-on-year but it has declined by 4% since the previous quarter
ENTX's gross margin is down by 20% since the previous quarter
The net income is down by 16% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of ENTX
Market
Valuations
Earnings
Shares outstanding
45.45M
Market cap
$93.18M
Enterprise value
$72.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.8
Price to sales (P/S)
398.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
326.56
Revenue
$223,000
Gross profit
$9,000
Operating income
-$10.09M
Net income
-$10.09M
EBIT
-$10.08M
EBITDA
-$10.04M
Free cash flow
-$6.37M
Per share
Balance sheet
Liquidity
EPS
-$0.26
EPS diluted
-$0.26
Free cash flow per share
-$0.15
Book value per share
$0.43
Revenue per share
$0.01
TBVPS
$0.5
Total assets
$21.6M
Total liabilities
$2.22M
Debt
$220,000
Equity
$19.38M
Working capital
$19.6M
Debt to equity
0.01
Current ratio
13.07
Quick ratio
12.75
Net debt/EBITDA
2.03
Margins
Efficiency
Dividend
EBITDA margin
-4,500.4%
Gross margin
4%
Net margin
-4,525.1%
Operating margin
-4,522.9%
Return on assets
-82.8%
Return on equity
-95.1%
Return on invested capital
N/A
Return on capital employed
-50.4%
Return on sales
-4,518.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTX stock price
How has the Entera Bio stock price performed over time
Intraday
-1.2%
1 week
11.72%
1 month
-13.14%
1 year
-2.38%
YTD
-3.3%
QTD
20.59%
Financial performance
How have Entera Bio's revenue and profit performed over time
Revenue
$223,000
Gross profit
$9,000
Operating income
-$10.09M
Net income
-$10.09M
Gross margin
4%
Net margin
-4,525.1%
Entera Bio's revenue has increased by 23% from the previous quarter
ENTX's gross margin is down by 20% since the previous quarter
The net income is down by 16% year-on-year and by 6% since the previous quarter
ENTX's operating income is down by 15% year-on-year and by 5% since the previous quarter
Price vs fundamentals
How does ENTX's price correlate with its fundamentals
Growth
What is Entera Bio's growth rate over time
Valuation
What is Entera Bio stock price valuation
P/E
N/A
P/B
4.8
P/S
398.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
326.56
The EPS is up by 7% year-on-year but it has declined by 4% since the previous quarter
The equity has surged by 140% since the previous quarter and by 119% year-on-year
ENTX's P/B is 40% below its last 4 quarters average of 8.0 and 2% below its 5-year quarterly average of 4.9
The stock's price to sales (P/S) is 41% less than its last 4 quarters average of 672.9 and 2.9% less than its 5-year quarterly average of 410.6
Entera Bio's revenue has increased by 23% from the previous quarter
Efficiency
How efficient is Entera Bio business performance
ENTX's return on equity is up by 20% since the previous quarter and by 8% year-on-year
Entera Bio's ROA has increased by 19% from the previous quarter and by 2.6% YoY
The return on sales is up by 14% since the previous quarter
Dividends
What is ENTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTX.
Financial health
How did Entera Bio financials performed over time
Entera Bio's total assets has soared by 130% from the previous quarter and by 111% YoY
The current ratio has surged by 71% since the previous quarter and by 50% year-on-year
The debt is 99% smaller than the equity
The equity has surged by 140% since the previous quarter and by 119% year-on-year
Entera Bio's debt to equity has plunged by 75% YoY and by 67% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.